Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888898 | 0.93 | OPRM1 (0.39) | ATMDRD2HPGDSIGMAR1HDAC1 | |
| SCHEMBL4893251 | 0.91 | P2RY1 (0.36) | P2RY1SLC18A3SIGMAR1HDAC1HDAC6 | |
| Trifluoroacetic Acid SCHEMBL4761896 | 0.88 | OPRM1 (0.36) | P2RY1SLC18A3SIGMAR1HDAC1HDAC6 | |
| SCHEMBL4893188 | 0.88 | NOTUM (0.43) | ATMDRD2HPGDHDAC1HDAC6 | |
| SCHEMBL4890954 | 0.87 | P2RX7 (0.40) | DRD2HPGDHDAC1HDAC6OPRM1 | |
| SCHEMBL4891915 | 0.87 | TACR1 (0.38) | P2RY1SLC18A3SIGMAR1HDAC1HDAC6 | |
| SCHEMBL4886704 | 0.85 | NOTUM (0.38) | P2RY1HDAC1HDAC6OPRM1FFAR1 | |
| SCHEMBL4887335 | 0.85 | NOTUM (0.39) | P2RY1SLC18A3SIGMAR1HDAC1HDAC6 | |
| SCHEMBL4893344 | 0.84 | OPRM1 (0.41) | SIGMAR1HDAC1HDAC6OPRM1FFAR1 | |
| SCHEMBL4890372 | 0.83 | P2RY1 (0.37) | P2RY1DRD2SLC18A3SIGMAR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | claimed |
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | ARENA PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2007002114-A1 | 1,2-DIHYDRO-SPIRO(3H-INDOLE-3-4’-PIPERIDINE) COMPOUNDS AS MODULATORS OF THE MAS RECEPTOR NOVEL | ARENA PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200491-A1 | 1,2-Dihydro-Spiro[3H-Indole-3,4'-Piperidine] Compounds, as Modulators of the Mas Receptor Novel | AGTR1, AGTR2, AVPR2 | ATM 2574/4885P2RY1 205/4885DRD2 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.